FIA
TTNP

FNY Investment Advisers’s Titan Pharmaceuticals TTNP Stock Holding History

FNY Investment Advisers’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,401
Closed -$30K – 750
2022
Q3 		$30K Buy
+1,401
New +$36.2K 0.02% 269

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
LFA
Level Financial Advisors East Amherst, New York $448M AUM 16.6% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FNY Investment Advisers's TTNP Position: Q4 2022 in Review

FNY Investment Advisers sold out of Titan Pharmaceuticals (TTNP) in Q4 2022, closing a stake of 1,401 shares — an estimated $30K sold.

FNY Investment Advisers first reported a position in TTNP in Q3 2022 and held it in 1 quarter. The position peaked at $30K in Q3 2022. 20 funds tracked by Wall St. Rank hold TTNP as of Q4 2022.

  • FNY Investment Advisers reported no remaining Titan Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 1,401 Titan Pharmaceuticals shares in Q4 2022, an estimated $30K.
  • FNY Investment Advisers first reported a position in Titan Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • FNY Investment Advisers's Titan Pharmaceuticals position peaked at $30K in Q3 2022.
  • 20 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2022.

Based on FNY Investment Advisers's 13F filing for Q4 2022, filed 10 Jan 2023.